Index to Volume 296

AUTHORS

Abraham NG (See Mitrione SM; Solangi K).
Allsbrook WC Jr (See Brubaker LH).
Amico JA, Finn FM, Haldar J. Oxytocin and Vasopressin Are Present in Human and Rat Pancreas 296(5):303–307.
Anthony LB (See Stratton CW).
Atkinson JR (See Tseng C-J).
Atsmon J. Topics in Clinical Pharmacology: Ipratropium Bromide in COPD and Asthma 296(2):140–142.
Aydelotte ME (See White WB).
Bajaj AK. Topics in Clinical Pharmacology: Enalapril: A Second-Generation Angiotensin Converting Enzyme Inhibitor 296(5):332–335.
Barnard JA, Bascom CC, Lyons RM, Sipes NJ, Moses HL. Transforming Growth Factor β in the Control of Epidermal Proliferation 296(3):159–163.
Barton JC (See Mulligan MJ).
Bascom CC (See Barnard JA).
Basilion JP (See Davies PJA).
Bechard D (See Glauser FL).
Beck J (See Brubaker LH).
Bell NH (See Hughes GS Jr).
Benner SE, Clark GM, McGuire WL. Review: Steroid Receptors, Cellular Kinetics, and Lymph Node Status as Prognostic Factors in Breast Cancer 296(1):59–66.
Berenson GS. Southern Society for Clinical Investigation and Its Future Viability 296(2):136–139.
Bernard GR (See Lucht WD).
Better OS (See Green J).
Bilhartz LE. Southwestern Internal Medicine Conference: Cholesterol Gallstone Disease: The Current Status of Nonsurgical Therapy 296(1):45–56.
Billett HH, Nagel RL, Fabry ME. Evolution of Laboratory Parameters During Sickle Cell Painful Crisis: Evidence Compatible with Dense Red Cell Sequestration Without Thrombosis 296(5):293–298.
Binkley PF (See Nicolozakes AW).
Blackmore PF. Hormonal Modulation of Cytosolic Free Calcium 296(4):246–248.
Blackshear PJ. Approaches to the Study of Protein Kinase C Involvement in Signal Transduction 296(4):231–240.
Bolds JM (See Duke SS).
Brannan DP (See Guthrie TH Jr).
Brenner B (See Green J).
Breslau NA. Southwestern Internal Medicine Conference: Normal and Abnormal Regulation of 1,25-$(OH)_2$D Synthesis 296(6):417–425.
Brigham KL (See Duke SS; Lucht WD).
Brubaker LH, Melhus O, Pantazis CG, Allsbrook WC Jr, Beck J, Martinez J. Case Report: Flow Cytometry Shows Recurrent Aneuploid Clone after Remission in Megakaryocytic Leukemia 296(5):327–331.
Butka B (See Lucht WD).
Campo L, Mylotte JM. Use of Microbiology Reports by Physicians in Prescribing Antimicrobial Agents 296(6):392–398.
Casner NA (See Zuckerman MJ).
Chan CK, Loke J, Snyder PE, Wackers F, Mattera J, Matthay RA. Oral Terbutaline Augments Cardiac Performance in Chronic Obstructive Pulmonary Disease 296(1):33–38.
Chandarlapaty SKC (See Kinney EL).
Chen Y-F, Yang R-H, Jin H, Wyss JM, Cragoe EJ, Oparil S. Rapid Communication: Exaggerated Depressor Response to 6-Iodoamiloride in NaCl-Sensitive Spontaneously Hypertensive Rats 296(1):78–83.
Chiocca EA (See Davies PJA).
Clark GM (See Benner SE).
Comaru-Schally AM, Kushner DS. Morning Report at Charity Hospital: Prostatic Carcinoma with Lung Metastases in a Former Bagasse Worker; LH-RH Analogs as an Alternative Therapy 296(5):348–353.
Connolly JF (See Strates BS).
Covington S (See Rossowski WJ).
Cragoe EJ (See Chen Y-F).
Davies PJA, Basilion JP, Chiocca EA, Johnson J, Poddar S, Stein JP. Retinoids as Generalized Regulators of Cellular Growth and Differentiation 296(3):164–170.
DeBlois G (See Glauser FL).
Dessypris EN (See Stone WJ).
Drusin R (See Schulman LL).
Duke SS, Bolds JM, Loyd JE, Brigham KL. Endotoxin-Induced Neutrophilic Alveolitis and Macrophage Chemotaxin Production in Sheep 296(6):381–386.
Dunlap DB (See Nelson DR).
Eisenberg S. Presentation of the Founder's Medal of the Southern Society for Clinical Investigation to Dr. Gerald S. Berenson 296(2):134–135.
El-Hinnawi SI (See Sedrani SH).
Elliot DL, Goldberg L, Luehl KS. Does Aerobic Conditioning Cause a Sustained Increase in the Metabolic Rate? 296(4):249–251.
Ellis DL (See King LE Jr).
Enson Y (See Schulman LL).
Epstein S (See Hughes GS Jr).
Ertan A (See Rossowski WJ).
Fabry ME (See Billett HH).
Fairman RP (See Glauser FL).
Farese RV. Calcium as an Intracellular Mediator of Hormone Action: Intracellular Phospholipid Signaling Systems 296(4):223–230.
Fava RA (See King LE Jr).
Feduccia TD, Scott-Conner CEH, Grogan JB. Profound Suppression of Lymphocyte Function in Early Biliary Obstruction 296(1):39–44.
Feldman JM (See Mortensen RM).
Fine J-D. Special Symposium, Southern Society for Investigative Dermatology: Growth and Differentiation of the Epidermis, New Orleans, Louisiana, February 1988 296(3):153.
Finkelstein R, Markel A, Putterman C, Lerman A, Hashman N, Merzbach D. Waterborne Typhoid Fever in Haifa, Israel: Clinical, Microbiologic, and Therapeutic Aspects of a Major Outbreak 296(1):27–32.
Finn FM (See Amico JA).
Firth BG. Southwestern Internal Medicine Conference: The Multifaceted Role of Angiotensin Converting Enzyme Inhibitors in Congestive Heart Failure 296(4):275–288.
Fowler AA (See Glauser FL).
Funck-Brentano C. Topics in Clinical Pharmacology: Encainide: A Useful New Antiarrhythmic Drug 296(1):76–77.
Gates RE (See King LE Jr).
Georges B (See Moreau BA).
Georgitis, WJ. Case Report: Densely Calcified Adrenals with Preserved Cortical Function 296(1):67–68.
Gery R (See Green J).
Gibbs MA (See Zuckerman MJ).
Glauser FL, DeBlois G, Bechard D, Fowler AA, Merchant R, Fairman RP. Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy 296(6): 406–412.
Goldberg L (See Elliot DL).
Goodman AI (See Solangi K).
Graber SE (See Stone WJ).
Graves J, Kenamond TG, Whittier FC. Acute Effects of Nifedipine on Renal Electrolyte Excretion in Normal and Hypertensive Subjects 296(2):114–118.
Green J, Brenner B, Gery R, Nachoul F, Lichtig C, Better OS. Case Report: Adult Hemolytic Uremic Syndrome Associated with Nonimmune Deposit Crescentic Glomerulonephritis and Alveolar Hemorrhage 296(2):121–125.
Griffin FM Jr (See Mulligan MJ).

Griffin JE. Southwestern Internal Medicine Conference: Management of Thyroid Nodules 296(5):336–347.
Grogan JB (See Feduccia TD).
Grossi CE (See Mulligan MJ).
Guthrie TH Jr, Brannan DP, Prisant LM. Idiopathic Thrombocytopenic Purpura in the Older Adult Patient 296(1):17–21.
Haldar J (See Amico JA).
Hashman N (See Finkelstein R).
Hashmonai N (See Hayek T).
Hayek T, Kleinhaus U, Hashmonai N, Keidar S. Case Report: Preoperative Diagnosis of Mirizzi Syndrome 296(1): 74–75.
Haynes RB. Selected Principles of the Measurement and Setting of Priorities of Death, Disability, and Suffering in Clinical Trials 296(5):364–369.
Hershey CO, Zizzi JA Jr. Assessing Clinical Experience in a Residency Training Program 296(6):371–376.
Hillis LD (See Lange RA).
Hu DCK, Wong EFC, Wong NLM. The Differential Response in Atrial Natriuretic Peptide Release During Exercise in Patients with and Without Ischemic Heart Disease 296(2):111–113.
Hughes GS Jr, Oexmann MJ, Margolius HS, Epstein S, Bell NH. Normal Vitamin D and Mineral Metabolism in Essential Hypertension 296(4):252–259.
Inman WH (See King LE Jr).
Israel F (See Kaplan A).
Jain AC (See Schmidt SB).
Jin H (See Chen Y-F).
Johnson J (See Davies PJA).
Johnston PE (See Stratton CW).
Kamm KE (See Stull JT).
Kapila A (see Mulligan MJ).
Kaplan A, Israel F. Resident Article: *Corynebacterium aquaticum* Infection in a Patient with Chronic Granulomatous Disease 296(1):57–58.
Keidar S (See Hayek T).
Kenamond TG (See Graves J).
King LE Jr, Ellis DL, Gates RE, Inman WH, Stoscheck CM, Fava RA, Nanney LB. The Role of Epidermal Growth Factor in Skin Diseases 296(3): 154–158.
Kinney EL, Chandarlapaty SKC. Case Report: Transient Myocardial Uptake of Tc-99m Methylene Diphosphonate in a Patient with Amyloidosis 296(6): 413–416.
Kleinhaus U (See Hayek T).
Kotchen TA (See Talwalkar RT).
Kraemer HC. Sample Size: When Is Enough Enough? 296(5):360–363.
Krantz SB (See Stone WJ).
Kremers MS. Southwestern Internal Medicine Conference: The Premise, Promise, and Perils of the Prevention of Lethal Ventricular Tachyarrhythmias 296(3):202–220.
Kuehl KS (See Elliot DL).
Kushner DS (See Comaru-Schally AM).
Lange RA, Hillis LD. Southwestern Internal Medicine Conference: Evolving Concepts in the Treatment of Acute Myocardial Infarction 296(2):143–152.
Leier CV (See Nicolozakes AW).
Lerman A (See Finkelstein R).
Lernhardt EB, Ziegler MG. Cough Caused by Cilazapril 296(2):119–120.
Levere RD (See Mitrione SM; Solangi K).
Lichtig C (See Green J).
Light RT (See Tseng C-J).
Loke J (See Chan CK).
Loyd JE (See Duke SS).
Lucht WD, Bernard GR, Butka B, Brigham KL. Corticosteroids Inhibit Endotoxin-Induced Lung Lymph Neutrophil Stimulating Activity in Sheep 296(2):98–102.
Lutton JD (See Mitrione SM).
Lyons RM (See Barnard JA).
Macik BG (See Passannante A).
Margolius HS (See Hughes GS Jr).
Markel A (See Finkelstein R).
Martinez J (See Brubaker LH).
Matsuoka T, Tavassoli M. A Modified Method for Application of Indirect Immunofluorescent Staining for Factor VIII/vWF to Capillary Endothelia 296(2):107–110.
Mattera J (See Chan CK).
Matthay RA (See Chan CK).
May G. Topics in Clinical Pharmacology: Imipenem, A New Broad Spectrum Antibiotic 296(4):289–291.
McCord R (See Rossowski WJ).
McGuire WL (See Benner SE).
Medoff J (See Mortensen RM).
Melhus O (See Brubaker LH).
Merchant R (See Glauser FL).
Merzbach D (See Finkelstein R).
Mitrione SM, Villalon P, Lutton JD, Levere RD, Abraham NG. Inhibition of Human Adult and Fetal Heme Oxygenase by New Synthetic Heme Analogues 296(3):180–186.
Moreau BA, Schuller E, Georges B. Case Report: Association of Guillain-Barré Syndrome and Henoch Schönlein Purpura: Is Immunoglobulin A Responsible for the Neurologic Syndrome? 296(3):198–201.
Morrow JD (See Willie RC).
Mortensen RM, Medoff J, Feldman JM. Case Report: Chylous Ascites and Carcinoid Tumors: Possible Association of Two Rare Disorders 296(4):272–274.
Moses HL (See Barnard JA).
Mulligan MJ, Vasu R, Grossi CE, Prasthofer EF, Griffin FM Jr, Kapila A, Trupp JM, Barton JC. Case Report: Neoplastic Meningitis with Eosinophilic Pleocytosis in Hodgkin's Disease: A Case with Cerebellar Dysfunction and a Review of the Literature 296(5):322–326.
Mylotte JM (See Campo L).
Nachoul F (See Green J).
Nagel RL (See Billett HH).
Nanney LB (See King LE Jr).
Nelson DR, Stachura ME, Punlap DB. Case Report: Ileal Carcinoid Tumor Complicated by Retroperitoneal Fibrosis and a Prolactinoma 296(2):129–133.
Nicolozakes AW, Binkley PF, Leier CV. Hemodynamic Effects of Smoking in Congestive Heart Failure 296(6):377–380.
Niefield S, Young EJ. Case Report: Native Valve Endocarditis Caused by Dysgonic Fermenter Type 2 Bacilli 296(1): 69–70.
Niki Y (See Umeki S).
Oexmann MJ (See Hughes GS Jr).
Olsen NJ (See Stone WJ).
O'Neil VL (See Stone WJ).
Oparil S (See Chen Y-F).
Ozden A (See Rossowski WJ).
Pantazis CG (See Brubaker LH).
Passannante A, Macik BG. Case Report: The Heparin Flush Syndrome: A Cause of Iatrogenic Hemorrhage 296(1):71–73.
Pincus TP (See Stone WJ).
Poddar S (See Davies PJA).
Prasthofer EF (See Mulligan MJ).
Prisant LM (See Guthrie TH Jr).
Putterman C (See Finkelstein R).
Reemtsma K (See Schulman LL).
Rice J (See Rossowski WJ).
Robertson D (See Tseng C-J).
Robertson RM (See Tseng C-J).
Rose EA (See Schulman LL).
Rossowski WJ, Ertan A, Rice J, Ozden A, Covington S, McCord R. Alterations in Cholinergic Muscarinic and Somatostatin Binding Sites in a Patient with Idiopathic Intestinal Pseudo-obstruction 296(6):399–405.
Sabra R. Topics in Clinical Pharmacology: Lovastatin 296(6):426–428.
Sacerdoti D (See Solangi K).
Schmidt SB, Jain AC. Diagnostic Utility of Memory Equipped Transtelephonic Monitors 296(5):299–302.
Schuller E (See Moreau BA).
Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. Respiratory Complications of Cardiac Transplantation 296(1):1–10.
Schwartzman ML (See Solangi K).
Scott-Conner CEH (See Feduccia TD).
Sears DA. History of the Treatment of Chronic Myelocytic Leukemia 296(2): 85–86.
Sedrani SH, El-Hinnawi SI, Warsy AS. Establishment of a Normal Reference Range for Alpha$_1$-Antitrypsin in Saudis Using Rate Nephelometry 296(1):22–26.
Sewell CW (See Watts NB).
Silverman WA. SSPR Mini-Symposium: Methodologic Controversies in Clinical Research: Consent for Experimentation Involving Neonates 296(5):354–359.
Sipes NJ (See Barnard JA).
Smith CR (See Schulman LL).
Snyder PE (See Chan CK).
Soejima R (See Umeki S).

Solangi K, Sacerdoti D, Goodman AI, Schwartzman ML, Abraham NG, Levere RD. Differential Effects of Partial Hepatectomy on Hepatic and Renal Heme and Cytochrome P450 Metabolism 296(6):387–391.
Stachura ME (See Nelson DR).
Stein JP (See Davies PJA).
Steinberg MH. Review: Thalassemia: Molecular Pathology and Management 296(5):308–321.
Stock AJ (See Strates BS).
Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ, Pincus TP. Treatment of the Anemia of Predialysis Patients with Recombinant Human Erythropoietin: A Randomized, Placebo-Controlled Trial 296(3):171–179.
Storb R. Bone Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia 296(2):87–94.
Stoscheck CM (See King LE Jr).
Strates BS, Stock AJ, Connolly JF. Skeletal Repair in the Aged: A Preliminary Study in Rabbits 296(4):266–269.
Stratton CW, Anthony LB, Johnston PE. Topics in Clinical Pharmacology: A Review of Ceftriaxone: A Long-Acting Cephalosporin 296(3):221–222.
Stull JT, Kamm KE, Taylor DA. Calcium Control of Smooth Muscle Contractility 296(4):241–245.
Talpaz M. The Activity of Alpha Interferons in Chronic Myelogenous Leukemia 296(2):95–97.
Talwalkar RT, Kotchen TA. Inhibition of Renin by Plasma Linoleic Acid 296(3):192–197.
Tavassoli M (See Matsuoka T).
Taylor DA (See Stull JT).
Trupp JM (See Mulligan MJ).
Tseng C-J, Robertson D, Light RT, Atkinson JR, Robertson RM. Neuropeptide Y Is a Vasoconstrictor of Human Coronary Arteries 296(1):11–16.
Umeki S, Niki Y, Soejima R. Elastase/Antielastase Systems in Pulmonary Diseases 296(2):103–106.
Vasu R (See Mulligan MJ).
Villalon P (See Mitrione SM).
Wackers F (See Chan CK).
Warsy AS (See Sedrani SH).
Watts NB, Sewel CW. Case Report: Carcinomatous Involvement of the Thyroid Presenting as Subacute Thyroiditis 296(2):126–128.
White WB, Aydelotte ME. Clinical Experience with Labetalol and Enalapril in Combination in Patients with Severe Essential and Renovascular Hypertension 296(3):187–191.
Whittier FC (See Graves J).
Wille RC, Morrow JD. Case Report: Dapsone Hypersensitivity Syndrome Associated with Treatment of the Bite of a Brown Recluse Spider 296(4):270–271.
Wong EFC (See Hu DCK).
Wong NLM (See Hu DCK).
Wyss JM (See Chen Y-F).
Yang R-H (See Chen Y-F).
Young EJ (See Niefield S).
Ziegler MG (See Lernhardt EB).
Zizzi JA Jr (See Hershey CO).
Zuckerman MJ, Casner NA, Gibbs MA. Application of an Immunofluorescence Assay for Crohn's Disease Using Primed Nude Mouse Lymph Nodes to a United States/Mexican Border Population 296(4):260–265.

TITLES

Acute Effects of Nifedipine on Renal Electrolyte Excretion in Normal and Hypertensive Subjects. Graves J, Kenamond TG, Whittier FC. 296(2): 114–118.
Alterations in Cholinergic Muscarinic and Somatostatin Binding Sites in a Patient with Idiopathic Intestinal Pseudo-obstruction. Rossowski WJ, Ertan A, Rice J, Ozden A, Covington S, McCord R. 296(6):399–405.
Application of an Immunofluorescence Assay for Crohn's Disease Using Primed Nude Mouse Lymph Nodes to a United States/Mexican Border Population. Zuckerman MJ, Casner NA, Gibbs MA. 296(4):260–265.
Assessing Clinical Experience in a Residency Training Program. Hershey CO, Zizzi JA Jr. 296(6):371–376.
Clinical Experience with Labetalol and Enalapril in Combination in Patients with Severe Essential and Renovascular Hypertension. White WB, Aydelotte ME. 296(3):187–191.
Corticosteroids Inhibit Endotoxin-Induced Lung Lymph Neutrophil Stimulating Activity in Sheep. Lucht WD, Bernard GR, Butka B, Brigham KL. 296(2):98–102.
Cough Caused by Cilazapril. Lernhardt EB, Ziegler MG. 296(2):119–120.
Diagnostic Utility of Memory Equipped Transtelephonic Monitors. Schmidt SB, Jain AC. 296(5):299–302.
Differential Effects of Partial Hepatectomy on Hepatic and Renal Heme and Cytochrome P450 Metabolism. Solangi K, Sacerdoti D, Goodman AI, Schwartzman ML, Abraham NG, Levere RD. 296(6):387–391.
The Differential Response in Atrial Natriuretic Peptide Release During Exercise in Patients with and without Ischemic Heart Disease. Hu DCK, Wong EFC, Wong NLM. 296(2): 111–113.
Does Aerobic Conditioning Cause a Sustained Increase in the Metabolic Rate? Elliot DL, Goldberg L, Kuehl KS. 296(4):249–251.
Elastase/Antielastase Systems in Pulmonary Diseases. Umeki S, Niki Y, Soejima R. 296(2):103–106.
Endotoxin-Induced Neutrophilic Alveolitis and Macrophage Chemotaxin Production in Sheep. Duke SS, Bolds JM, Loyd JE, Brigham KL. 296(6):381–386.
Establishment of a Normal Reference Range for Alpha$_1$-Antitrypsin in Saudis Using Rate Nephelometry. Sedrani SH, El-Hinnawi SI, Warsy AS. 296(1):22–26.
Evolution of Laboratory Parameters During Sickle Cell Painful Crisis: Evidence Compatible with Dense Red Cell Sequestration Without Thrombosis. Billett HH, Nagel RL, Fabry ME. 296(5):293–298.
Hemodynamic Effects of Smoking in Congestive Heart Failure. Nicolozakes AW, Binkley PF, Leier CV. 296(6):377–380.
Idiopathic Thrombocytopenic Purpura in the Older Adult Patient. Guthrie TH Jr, Brannan DP, Prisant LM. 296(1):17–21.
Inhibition of Human Adult and Fetal Heme Oxygenase by New Synthetic Heme Analogues. Mitrione SM, Villalon P, Lutton JD, Levere RD, Abraham NG. 296(3):180–186.
Inhibition of Renin by Plasma Linoleic Acid. Talwalkar RT, Kotchen TA. 296(3):192–197.
A Modified Method for Application of Indirect Immunofluorescent Staining for Factor VIII/vWF to Capillary Endothelia. Matsuoka T, Tavassoli M. 296(2):107–110.
Neuropeptide Y Is a Vasoconstrictor of Human Coronary Arteries. Tseng C-J, Robertson D, Light RT, Atkinson JR, Robertson RM. 296(1):11–16.
Normal Vitamin D and Mineral Metabolism in Essential Hypertension. Hughes GS Jr, Oexmann MJ, Margolius HS, Epstein S, Bell NH. 296(4):252–259.
Oral Terbutaline Augments Cardiac performance in Chronic Obstructive Pulmonary Disease. Chan CK, Loke J, Snyder PE, Wackers F, Mattera J, Matthay RA. 296(1):33–38.
Oxytocin and Vasopressin Are Present in Human and Rat Pancreas. Amico JA, Finn FM, Haldar J. 296(5): 303–307.
Profound Suppression of Lymphocyte Function in Early Biliary Obstruction. Feduccia TD, Scott-Conner CEH, Grogan JB. 296(1):39–44.
Respiratory Complications of Cardiac Transplantation. Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. 296(1):1–10.
Skeletal Repair in the Aged: A Preliminary Study in Rabbits. Strates BS, Stock AJ, Connolly JF. 296(4):266–269.
Treatment of the Anemia of Predialysis Patients with Recombinant Hu-

man Erythropoietin: A Randomized, Placebo-Controlled Trial. Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ, Pincus TP. 296(3):171–179.

Use of Microbiology Reports by Physicians in Prescribing Antimicrobial Agents. Campo L, Mylotte JM. 296(6): 392–398.

Waterborne Typhoid Fever in Haifa, Israel: Clinical, Microbiologic, and Therapeutic Aspects of a Major Outbreak. Finkelstein R, Markel A, Putterman C, Lerman A, Hashman N, Merzbach D. 296(1):27–32.

Case Reports

Adult Hemolytic Uremic Syndrome Associated with Nonimmune Deposit Crescentic Glomerulonephritis and Alveolar Hemorrhage. Green J, Brenner B, Gery R, Nachoul F, Lichtig C, Better OS. 296(2):121–125.

Association of Guillain-Barré Syndrome and Henoch-Schönlein Purpura: Is Immunoglobulin A Responsible for the Neurologic Syndrome? Moreau BA, Schuller E, Georges B. 296(3):198–201.

Carcinomatous Involvement of the Thyroid Presenting as Subacute Thyroiditis. Watts NB, Sewell CW. 296(2):126–128.

Chylous Ascites and Carcinoid Tumors: Possible Association of Two Rare Disorders. Mortensen RM, Medoff J, Feldman JM. 296(4):272–274.

Dapsone Hypersensitivity Syndrome Associated with Treatment of the Bite of a Brown Recluse Spider. Wille RC, Morrow JD. 296(4):270–271.

Densely Calcified Adrenals with Preserved Cortical Function. Georgitis WJ. 296(1):67–68.

Flow Cytometry Shows Recurrent Aneuploid Clone after Remission in Megakaryocytic Leukemia. Brubaker LH, Melhus O, Pantazis CG, Allsbrook WC Jr, Beck J, Martinez J. 296(5):327–331.

The Heparin Flush Syndrome: A Cause of Iatrogenic Hemorrhage. Passannante A, Macik BG. 296(1):71–73.

Ileal Carcinoid Tumor Complicated by Retroperitoneal Fibrosis and a Prolactinoma. Nelson DR, Stachura ME, Dunlap DB. 296(2):129–133.

Native Valve Endocarditis Caused by Dysgonic Fermeter Type 2 Bacilli. Niefield S, Young EJ. 296(1):69–70.

Neoplastic Meningitis with Eosinophilic Pleocytosis in Hodgkin's Disease: A Case with Cerebellar Dysfunction and a Review of the Literature. Mulligan MJ, Vasu R, Grossi CE, Prasthofer EF, Griffin FM Jr, Kapila A, Trupp JM, Barton JC. 296(5): 322–326.

Preoperative Diagnosis of Mirizzi Syndrome. Hayek T, Kleinhaus U, Hashmonai N, Keidar S. 296(1):74–75.

Transient Myocardial Uptake of Tc-99m Methylene Diphosphonate in a Patient with Amyloidosis. Kinney EL, Chandarlapaty SKC. 296(6):413–416.

Reviews

Cardiopulmonary Toxicity of Adoptive Immunotherapy. Glauser FL, DeBlois G, Bechard D, Fowler AA, Merchant R, Fairman RP. 296(6):406–412.

Steroid Receptors, Cellular Kinetics, and Lymph Node Status as Prognostic Factors in Breast Cancer. Benner SE, Clark GM, McGuire WL. 296(1):59–66.

Thalassemia: Molecular Pathology and Management. Steinberg MH. 296(5):308–321.

Southwestern Internal Medicine Conference

Cholesterol Gallstone Disease: The Current Status of Nonsurgical Therapy. Bilhartz LE. 296(1):45–56.

Evolving Concepts in the Treatment of Acute Myocardial Infarction. Lange RA, Hillis LD, 296(2):143–152.

Management of Thyroid Nodules. Griffin JE. 296(5):336–347.

The Multifaceted Role of Angiotensin Converting Enzyme Inhibitors in Congestive Heart Failure. Firth BG. 296(4):275–288.

Normal and Abnormal Regulation of 1,25-$(OH)_2$D Synthesis. Breslau NA. 296(6):417–425.

The Premise, Promise, and Perils of the Prevention of Lethal Ventricular Tachyarrhythmias. Kremers MS. 296(3):202–220.

Mini-Symposium: Calcium as an Intracellular Mediator of Hormone Action

Approaches to the Study of Protein Kinase C Involvement in Signal Transduction. Blackshear PJ. 296(4): 231–240.

Calcium Control of Smooth Muscle Contractility. Stull JT, Kamm KE, Taylor DA. 296(4):241–245.

Hormonal Modulation of Cytosolic Free Calcium. Blackmore PF. 296(4): 246–248.

Intracellular Phospholipid Signaling Systems. Farese RV. 296(4):223–230.

Morning Report at Charity Hospital

Prostatic Carcinoma with Lung Metastases in a Former Bagasse Worker; LH-RH Analogs as an Alternative Therapy. Comaru-Schally AM, Kushner DS. 296(5):348–353.

Rapid Communication

Exaggerated Depressor Response to 6-Iodoamiloride in NaCl-Sensitive Spontaneously Hypertensive Rats. Chen Y-F, Yang R-H, Jin H, Wyss JM, Cragoe EJ, Oparil S. 296(1):78–83.

Resident Article

Corynebacterium aquaticum Infection in a Patient with Chronic Granulomatous Disease. Kaplan A, Israel F. 296(1): 57–58.

Southern Blood Clues Symposium: New Treatments for Chronic Myelocytic Leukemia

The Activity of Alpha Interferons in Chronic Myelogenous Leukemia. Talpaz M. 296(2):95–97.

Bone Marrow Transplantation for the Treatment of Chronic Myelogenous Leukemia. Storb R. 296(2):87–94.

History of the Treatment of Chronic Myelocytic Leukemia. Sears DA. 296(2):85–86.

Special Feature

Presentation of the Founder's Medal of the Southern Society for Clinical Investigation to Dr. Gerald S. Berenson. Eisenberg S. 296(2):134–135.

Southern Society for Clinical Investigation and Its Future Viability. Berenson GS. 296(2):136–139.

Special Symposium, Southern Society for Investigative Dermatology: Growth and Differentiation of the Epidermis, New Orleans, Louisiana, February 1988

Introduction. Fine J-D. 296(3):153.

Retinoids as Generalized Regulators of Cellular Growth and Differentiation. Davies PJA, Basilion JP, Chiocca EA, Johnson J, Poddar S, Stein JP. 296(3):164–170.

The Role of Epidermal Growth Factor in Skin Diseases. King LE Jr, Ellis DL, Gates RE, Inman WH, Stoscheck CM, Fava RA, Nanney LB. 296(3):154–158.

Transforming Growth Factor β in the Control of Epidermal Proliferation. Barnard JA, Bascom CC, Lyons RM, Sipes NJ, Moses HL. 296(3):159–163.

SSPR mini-symposium: Methodologic Controversies in Clinical Research

Consent for Experimentation Involving Neonates. Silverman WA. 296(5): 354–359.

Sample Size: When Is Enough Enough? Kraemer HC. 296(5):360–363.

Selected Principles of the Measurement and Setting of Priorities of Death, Disability, and Suffering in Clinical Trials. Haynes RB. 296(5): 364–369.

Topics in Clinical Pharmacology
Enalapril: A Second-Generation Angiotensin Converting Enzyme Inhibitor. Bajaj AK. 296(5):332–335.
Encainide: A Useful New Antiarrhythmic Drug. Funck-Brentano C. 296(1):76–77.
Imipenem, A New Broad Spectrum Antibiotic. May G. 296(4):289–291.
Ipratropium Bromide in COPD and Asthma. Atsmon J. 296(2):140–142.
Lovastatin. Sabra R. 296(6):426–428.
A Review of Ceftriaxone: A Long-Acting Cephalosporin. Stratton CW, Anthony LB, Johnston PE. 296(3):221–222.

Key Indexing Terms
Absorptive hypercalciuria 296(6):417–425
ACE inhibitors 296(2):119–120
ACE inhibitors 296(3):187–191
ACE inhibitors 296(4):275–288
ACE inhibitors 296(5):332–335
Acute myocardial infarction 296(2):143–152
Adenocarcinoma 296(2):126–128
Adoptive immunotherapy 296(6):406–412
Adrenal glands 296(1):67–68
Adrenal insufficiency 296(1):67–68
Adult hemolytic uremic syndrome 296(2):121–125
Adult respiratory distress syndrome 296(2):98–102
Aerobic conditioning 296(4):249–251
Affinity chromatography 296(3):192–197
Aging 296(4):266–269
ALA synthase 296(6):387–391
Alpha$_1$-antitrypsin 296(1):22–26
Alpha$_1$-antitrypsin 296(2):103–106
Alpha interferons 296(2):95–97
Alveolar hemorrhage 296(2):121–125
Alveolitis 296(6):381–386
δ-Aminolevulinic acid synthase 296(6):387–391
Ampicillin 296(1):27–32
Amyloidosis 296(6):413–416
Anemia 296(3):171–179
Aneuploidy 296(5):327–331
Angiotensin-converting enzyme inhibitors 296(2):119–120
Angiotensin-converting enzyme inhibitors 296(3):187–191
Angiotensin-converting enzyme inhibitors 296(4):275–288
Angiotensin-converting enzyme inhibitors 296(5):332–335
Anticoagulation 296(1):71–73
Antimicrobial prescribing 296(6):392–398
Antimicrobial susceptibility 296(6):392–398
α_1-Antitrypsin 296(1):22–26
α_1-Antitrypsin 296(2):103–106
APACHE II 296(6):371–376
Ara-C 296(5):327–331
ARDS 296(2):98–102
Arrhythmia 296(1):76–77
Arrhythmia 296(3):202–220
Arrhythmias 296(5):299–302
Arterial pressure 296(1):78–83
Ascites 296(4):272–274
Aspiration biopsy cytology 296(5):336–347
Asthma 296(2):140–142
Atrial natriuretic peptide 296(2):111–113
Autocrine hypothesis 296(3):159–163
Azathioprine 296(1):1–10
Bagasse worker 296(5):348–353
Biliary obstruction 296(1):39–44
Bilirubin 296(5):293–298
Blood cultures 296(1):27–32
Blood pressure 296(1):78–83
Blood pressure 296(2):114–118
Blood pressure 296(3):187–191
Blood pressure 296(4):252–259
Bone 296(4):266–269
Bone marrow 296(4):266–269
Bone marrow progenitors 296(3):171–179
Bone marrow transplantation 296(2):87–94
Bone scans 296(6):413–416
Breast cancer 296(1):59–66
Brown recluse spider 296(4):270–271
Ca^{2+} 296(4):241–245
Calcium 296(2):114–118
Calcium 296(4):223–230
Calcium 296(4):241–245
Calcium 296(4):246–248
Calcium 296(4):252–259
Calcium channel blockers 296(2):114–118
Calcium excretion 296(2):114–118
Calmodulin 296(4):241–245
Cancer 296(1):59–66
Cancer 296(2):126–128
Cancer 296(5):336–347
Cancer 296(5):348–353
Cancer 296(6):413–416
Capillary endothelium 296(2):107–110
Captopril 296(2):119–120
Captopril 296(4):275–288
Carcinoid syndrome 296(4):272–274
Carcinoid tumor 296(2):129–133
Carcinoid tumor 296(4):272–274
Carcinoma 296(2):126–128
Carcinoma 296(5):348–353
Cardiac function 296(1):33–38
Cardiac transplantation 296(1):1–10
Cardiopulmonary toxicity 296(6):406–412
Ceftriaxone 296(3):221–222
Cellular function 296(3):154–158
Cellular growth and differentiation 296(3):164–170
Cellular kinetics 296(1):59–66
Cephalosporins 296(3):221–222
Cerebellum 296(5):324–326
Cerebrospinal fluid 296(3):198–201
Chemotaxin production 296(6):381–386
Chenodiol 296(1):45–56
Chloramphenicol 296(1):27–32
Cholecystectomy 296(1):45–56
Cholecystectomy 296(1):74–75
Cholesterol 296(6):426–428
Cholesterol gallstones 296(1):45–56
Cholinergic muscarinic binding sites 296(6):399–405
Chronic granulomatous disease 296(1):57–58
Chronic myelocytic leukemia 296(2):85–86
Chronic myelocytic leukemia 296(2):87–94
Chronic myelocytic leukemia 296(2):95–97
Chronic obstructive pulmonary disease 296(1):33–38
Chronic obstructive pulmonary disease 296(2):140–142
Chylous ascites 296(4):272–274
Cigarette smoking 296(6):377–380
Cilazapril 296(2):119–120
Clinical experience 296(6):371–376
Clinical research 296(5):354–359
Clinical research 296(5):360–363
Clinical research 296(5):364–369
Clone 296(5):327–331
Colitis 296(4):260–265
Collagen 296(4):266–269
Common hepatic duct obstruction 296(1):74–75
Complement decrease 296(3):198–201
Concanavalin A 296(1):39–44
Congestive heart failure 296(4):275–288
Congestive heart failure 296(6):377–380
Contraction 296(4):241–245
Contraction 296(4):241–245
Coronary artery 296(1):11–16
Coronary reperfusion 296(2):143–152
Corynebacterium aquaticum 296(1):57–58
Cough 296(2):119–120
Crescentic glomerulonephritis 296(2):121–125
Crohn's disease 296(4):260–265
Cyclic adenosine monophosphate 296(6):417–425
Cyclosporine 296(1):1–10
Cytochrome P450 296(6):387–391
Cystosine arabinoside 296(5): 327–331
Cytosolic free calcium 296(4):246–248
Dapsone 296(4):270–271
1,25-$(OH)_2$D 296(6):417–425
Death 296(5):364–369
Demineralized bone matrix 296(4):266–269
Dense red cell sequestration 296(5):293–298
Depressor response 296(1):78–83
DF-2 infection 296(1):69–70
Diagnostic use 296(6):413–416
Diaminodiphenylsulfone 296(4):270–271
Diet 296(4):252–259
1,25–Dihydroxyvitamin D 296(6):417–425
Disability 296(5):364–369
DNA label 296(5):317–321
Elastase 1 296(2):103–106
Elderly 296(1):17–21
Elderly 296(4):266–269
Electrolyte excretion 296(2):114–118
Enalapril 296(2):119–120
Enalapril 296(3):187–191
Enalapril 296(4):275–288
Enalapril 296(5):332–335
Encainide 296(1):76–77
Endocarditis 296(1):69–70
Endotoxin 296(2):98–102
Endotoxin 296(6):381–386
Eosinophil 296(5):322–326
Epidermal growth factor 296(3):154–158
Epidermal proliferation 296(3):159–163
Epidermis 296(3):153
Epidermis 296(3):164–170
Erythropoietin 296(3):171–179
Essential hypertension 296(3):187–191
Essential hypertension 296(4):252–259
Estrogen receptor 296(1):59–66
Estrogens 296(6):417–425
Exercise 296(2):111–113

Exercise 296(4):249–251
Exertion 296(4):249–251
Extracorporeal shock waves 296(1):45–56
Extraskeletal implants 296(4):266–269
Factor VIII/vWF antigen 296(2):107–110
Flow cytometry 296(1):59–66
Flow cytometry 296(5):327–331
Founder's Medal 296(2):134–135
Glomerulonephritis 296(2):121–125
Gram-negative endocarditis 296(1):69–70
Growth factors 296(3):154–158
Guillain-Barré syndrome 296(3):198–201
Heart failure 296(4):275–288
Heart failure 296(6):377–380
Heart transplantation 296(1):1–10
Heme 296(3):180–186
Heme oxygenase 296(3):180–186
Heme oxygenase 296(6):387–391
Hemodynamics 296(6):377–380
Hemorrhage 296(1):71–73
Hemorrhage 296(2):121–125
Henoch-Schönlein purpura 296(3):198–201
Heparin flush syndrome 296(1):71–73
Hepatectomy 296(6):387–391
Hodgkin's disease 296(5):322–326
Human liver 296(3):180–186
5-Hydroxyindoleacetic acid 296(4):272–274
Hypercalcemia 296(6):417–425
Hypercholesterolemia 296(6):426–428
Hypersensitivity 296(4):270–271
Hypertension 296(1):78–83
Hypertension 296(2):114–118
Hypertension 296(3):187–191
Hypertension 296(4):252–259
Hyperthyroidism 296(2):126–128
Hypocalcemia 296(6):417–425
Hypophosphatemic rickets 296(6):417–425
Hypotension 296(6):406–412
Idiopathic intestinal pseudo-obstruction 296(6):399–405
Idiopathic thrombocytopenic purpura 296(1):17–21
IgA aggregates 296(3):198–201
IL-2 296(6):406–412
Ileal carcinoid tumor 296(2):129–133
Imipenem 296(4):289–291
Immunocompromised host 296(1):1–10
Immunofluorescence assay 296(4):260–265
Immunofluorescent method 296(2):107–110
Immunoglobulin A 296(3):198–201
Immunology 296(1):39–44
Indirect bilirubin 296(5):293–298
Inflammatory bowel disease 296(4):260–265
Interferons 296(2):95–97
Interleukin-2 activated lymphocytes 296(6):406–412
Interleukin-2 296(6):406–412
Intestinal pseudo-obstruction 296(6):399–405
Intracellular signaling 296(4):223–230
6-Iodoamiloride 296(1):78–83
Ipratropium bromide 296(2):140–142
Ischemic heart disease 296(2):111–113
Jaundice 296(1):39–44
Kidney 296(6):387–391
Labetalol 296(3):187–191
Laboratory use 296(6):392–398
LAK cell phenomena 296(6):406–412
LAK cells 296(6):406–412
Left ventricular ejection fraction 296(1):33–38
Leukemia 296(2):85–86
Leukemia 296(2):87–94
Leukemia 296(2):95–97
Leukemia 296(5):327–331
LH-RH analogs 296(5):348–353
Linoleic acid 296(3):192–197
Lisinopril 296(4):275–288
Liver 296(1):39–44
Liver 296(6):387–391
Liver cell fractionation 296(2):107–110
Liver endothelium 296(2):107–110
Long-acting cephalosporins 296(3):221–222
Lovastatin 296(6):426–428
Lung injury 296(2):98–102
Lung injury 296(6):381–386
Lung metastases 296(5):348–353
Luteinizing hormone-releasing hormone 296(5):348–353
Lymph nodes 296(1):59–66
Lymphocytes 296(1):39–44
Lymphokine activated killer cells 296(6):406–412
α_1-Macroglobulin 296(2):103–106
Macrophages 296(6):381–386
Medical residents 296(6):371–376
Megakaryocytic leukemia 296(5):327–331
Membrane sodium channel activity 296(1):78–83
Memory-equipped transtelephonic monitors 296(5):299–302
Meningitis 296(5):322–326
Metabolic rate 296(4):249–251
Metastatic carcinoma 296(2):126–128
Metastatic carcinoma 296(5):348–353
Methyl tertiary butyl ether 296(1):45–56
Mevacor 296(6):426–428
Microbiology reports 296(6):392–398
Mirizzi syndrome 296(1):74–75
Mononucleosis syndrome 296(4):270–271
Mouse submaxillary renin 296(3):192–197
Multimers 296(2):121–125
Myocardial disease 296(6):413–416
Myocardial infarction 296(2):143–152
Myosin 296(4):241–245
Myosin light chain kinase 296(4):241–245
Neonates 296(5):354–359
Neoplastic meningitis 296(5):322–326
Nephelometry 296(1):22–26
Neurohypophysial peptides 296(5):303–307
Neuropeptide Y 296(1):11–16
Neutrophils 296(2):98–102
Neutrophils 296(6):381–386
New bone formation 296(4):266–269
Nicotine 296(6):377–380
Nifedipine 296(2):114–118
Noradrenaline 296(1):11–16
Normal reference range 296(1):22–26
Nude mice 296(4):260–265
Older adult 296(1):17–21
Older adult 296(4):266–269
Oral terbutaline 296(1):33–38
Osteogenesis 296(4):266–269
Oxytocin 296(5):303–307
Pancreas 296(5):303–307
Parathyroid hormone 296(6):417–425
Partial hepatectomy 296(6):387–391
Philadelphia chromosome 296(2):95–97
Phosphate deprivation and loading 296(6):417–425
Phospholipid metabolism 296(4):223–230
Phosphorylation 296(4):241–245
Plasminogen activator 296(2):143–152
Platelet factor 4 296(5):293–298
Pleocytosis 296(5):322–326
Pneumonitis 296(1):1–10
Progesterone receptor 296(1):59–66
Prolactinoma 296(2):129–133
Prostatic cancer 296(5):348–353
Prostatic cancer 296(6):413–416
Protein kinase C 296(4):231–240
Proto-oncogenes 296(1):59–66
Pseudohypoparathyroidism 296(6):417–425
Pseudo-obstruction 296(6):399–405
Pulmonary microvascular permeability 296(6):406–412
Rate nephelometry 296(1):22–26
Rats 296(1):39–44
Recombinant erythropoietin 296(3):171–179
Recovery energy expenditure 296(4):249–251
Red cell mass 296(3):171–179
Reed-Sternberg cell 296(5):322–326
Regional enteritis 296(4):260–265
Relapse 296(1):27–32
Renal electrolyte excretion 296(2):114–118
Renal failure 296(3):171–179
Renal metabolism 296(6):387–391
Renin inhibitor 296(3):192–197
Renovascular hypertension 296(3):187–191
Research 296(5):354–359
Research 296(5):360–363
Research 296(5):364–369
Respiratory diseases 296(2):103–106
Respiratory infection 296(1):1–10
Retinoids 296(3):164–170
Retroperitoneal fibrosis 296(2):129–133
Right ventricular ejection fraction 296(1):33–38
Salt 296(1):78–83
Sample size 296(5):360–363
Saudi Arabia 296(1):22–26
Second messengers 296(4):241–245
Serotonin 296(4):272–274
Severe hypertension 296(3):187–191
Sheep 296(6):381–386
SHR 296(1):78–83
Sickle cell anemia 296(5):293–298
Signal transduction 296(4):231–240
Skeletal repair 296(4):266–269
Skin 296(3):164–170
Skin diseases 296(3):154–158
Smoking 296(6):377–380
Smooth muscle 296(4):241–245
Sodium 296(4):252–259
Sodium channel blocker 296(1):78–83
Sodium excretion 296(2):114–118
Somatostatin binding sites 296(6):399–405
Southern Society for Clinical Investigation 296(2):134–135
Southern Society for Clinical Investigation 296(2):136–139
Spider bite 296(4):270–271
Splenocytes 296(1):39–44

Spontaneously hypertensive rats 296(1): 78–83
Steroid receptors 296(1):59–66
Steroids 296(2):98–102
Streptokinase 296(2):143–152
Subacute thyroiditis 296(2):126–128
Substrate dependency 296(6):417–425
Sudden death 296(3):202–220
Suffering 296(5):364–369
Susceptibility testing 296(6):392–398
Systemic hypotension 296(6):406–412
Tachyarrhythmias 296(3):202–220
Tc-99m medronate 296(6):413–416
Technetium 99m medronate 296(6):413–416
Terbutaline 296(1):33–38
Thalassemia 296(5):308–321
Thrombocytopenia 296(2):121–125
β-Thromboglobulin 296(5):293–298
Thrombolytic therapy 296(2):143–152
Thyroidal metastases 296(2):126–128
Thyroid cancer 296(5):336–347
Thyroiditis 296(2):126–128
Thyroid nodules 296(5):336–347
Tin protoporphyrin 296(3):180–186
Tissue plasminogen activator 296(2):143–152
Tobacco 296(6):377–380
Training programs 296(6):371–376
Transforming growth factor β 296(3):159–163
Transient myocardial uptake 296(6):413–416
Transtelephonic monitoring 296(5):299–302
Treatment 296(1):27–32
Tumoral calcinosis 296(6):417–425
Typhoid fever 296(1):27–32
Typhoid hepatitis 296(1):27–32
Ulcerative colitis 296(4):260–265
Ursodeoxycholic acid 296(1):45–56
Vasoconstriction 296(1):11–16
Vasopressin 296(5):303–307
Vasorelaxation 296(1):11–16
Ventricular fibrillation 296(3):202–220
Ventricular tachycardia 296(3):202–220
Vitamin D 296(4):252–259
von Willebrand factor 296(2):107–110
von Willebrand factor 296(2):121–125
Waterborne epidemic 296(1):27–32
Work load 296(6):371–376